325 related articles for article (PubMed ID: 23874596)
21. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K; Mishin VP; Deyde VM; Furuta Y; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2010 Jun; 54(6):2517-24. PubMed ID: 20350949
[TBL] [Abstract][Full Text] [Related]
22. Detailed Analyses of Molecular Interactions between Favipiravir and RNA Viruses In Silico.
Shirai T; Sada M; Saraya T; Kurai D; Sunagawa S; Ishii H; Kimura H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215932
[TBL] [Abstract][Full Text] [Related]
23. Simple
Lu G; Bluemling GR; Mao S; Hager M; Gurale BP; Collop P; Kuiper D; Sana K; Painter GR; De La Rosa A; Kolykhalov AA
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180528
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Ribonucleotide 5'-Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase by Using Nonradioactive Polymerase Assays.
Lu G; Bluemling GR; Collop P; Hager M; Kuiper D; Gurale BP; Painter GR; De La Rosa A; Kolykhalov AA
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993851
[TBL] [Abstract][Full Text] [Related]
25. Antiviral Effect of Favipiravir (T-705) against Measles and Subacute Sclerosing Panencephalitis Viruses.
Hashimoto K; Maeda H; Miyazaki K; Watanabe M; Norito S; Maeda R; Kume Y; Ono T; Chishiki M; Suyama K; Sato M; Hosoya M
Jpn J Infect Dis; 2021 Mar; 74(2):154-156. PubMed ID: 32863356
[TBL] [Abstract][Full Text] [Related]
26. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.
Delang L; Abdelnabi R; Neyts J
Antiviral Res; 2018 May; 153():85-94. PubMed ID: 29524445
[TBL] [Abstract][Full Text] [Related]
27. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
[TBL] [Abstract][Full Text] [Related]
28. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.
Fung A; Jin Z; Dyatkina N; Wang G; Beigelman L; Deval J
Antimicrob Agents Chemother; 2014 Jul; 58(7):3636-45. PubMed ID: 24733478
[TBL] [Abstract][Full Text] [Related]
29. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity of ribavirin and favipiravir against human astroviruses.
Janowski AB; Dudley H; Wang D
J Clin Virol; 2020 Feb; 123():104247. PubMed ID: 31864069
[TBL] [Abstract][Full Text] [Related]
31. Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing.
Goldhill DH; Langat P; Xie H; Galiano M; Miah S; Kellam P; Zambon M; Lackenby A; Barclay WS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381482
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
33. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
[TBL] [Abstract][Full Text] [Related]
34. The mechanism of resistance to favipiravir in influenza.
Goldhill DH; Te Velthuis AJW; Fletcher RA; Langat P; Zambon M; Lackenby A; Barclay WS
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11613-11618. PubMed ID: 30352857
[TBL] [Abstract][Full Text] [Related]
35. Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein.
Tchesnokov EP; Bailey-Elkin BA; Mark BL; Götte M
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008283. PubMed ID: 32497085
[TBL] [Abstract][Full Text] [Related]
36. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir).
Huchting J; Vanderlinden E; Van Berwaer R; Meier C; Naesens L
Antiviral Res; 2019 Jul; 167():1-5. PubMed ID: 30951731
[TBL] [Abstract][Full Text] [Related]
37. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP.
Naydenova K; Muir KW; Wu LF; Zhang Z; Coscia F; Peet MJ; Castro-Hartmann P; Qian P; Sader K; Dent K; Kimanius D; Sutherland JD; Löwe J; Barford D; Russo CJ
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33526596
[TBL] [Abstract][Full Text] [Related]
38. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.
Baranovich T; Wong SS; Armstrong J; Marjuki H; Webby RJ; Webster RG; Govorkova EA
J Virol; 2013 Apr; 87(7):3741-51. PubMed ID: 23325689
[TBL] [Abstract][Full Text] [Related]
39. T-705 (favipiravir) inhibition of arenavirus replication in cell culture.
Mendenhall M; Russell A; Juelich T; Messina EL; Smee DF; Freiberg AN; Holbrook MR; Furuta Y; de la Torre JC; Nunberg JH; Gowen BB
Antimicrob Agents Chemother; 2011 Feb; 55(2):782-7. PubMed ID: 21115797
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir.
Tchesnokov EP; Feng JY; Porter DP; Götte M
Viruses; 2019 Apr; 11(4):. PubMed ID: 30987343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
